# IMPFGEFLÜSTER
15.04.202507:40
Liebe #IMPFGEFLÜSTER Fans!
Wir wünschen Ihnen eine schöne Karwoche und ein frohes Osterfest!
Nach Ostern geht es mit #IMPFGEFLÜSTER Staffel 6 weiter.
In der ersten Folge beschäftigen wir uns mit der sogenannten "Krebs Impfung " HPV. Die ersten Impfbusse sind in Österreich seit 3.4.25 unterwegs.
Die Folge 2 wird sie über die unfassbaren Erkenntnisse des Gerichtsverfahrens gegen die Hersteller des HPV Impfstoffs informieren. In den Medien kein Wort!
LG Ihr #IMPFGEFLÜSTER Team
Wir wünschen Ihnen eine schöne Karwoche und ein frohes Osterfest!
Nach Ostern geht es mit #IMPFGEFLÜSTER Staffel 6 weiter.
In der ersten Folge beschäftigen wir uns mit der sogenannten "Krebs Impfung " HPV. Die ersten Impfbusse sind in Österreich seit 3.4.25 unterwegs.
Die Folge 2 wird sie über die unfassbaren Erkenntnisse des Gerichtsverfahrens gegen die Hersteller des HPV Impfstoffs informieren. In den Medien kein Wort!
LG Ihr #IMPFGEFLÜSTER Team
13.03.202521:08
https://doi.org/10.1371/journal.ppat.1004902
Vijaykrishna, D., Mukerji, R., & Smith, G. J. D. (2015). RNA Virus Reassortment: An Evolutionary Mechanism for Host Jumps and Immune Evasion. PLoS Pathogens, 11(7), e1004902.
https://doi.org/10.1136/bmj.l4151
Walsh, L. K., Donelle, J., Dodds, L., Hawken, S., Wilson, K., Benchimol, E. I., Chakraborty, P., Guttmann, A., Kwong, J. C., MacDonald, N. E., Ortiz, J. R., Sprague, A. E., Top, K. A., Walker, M. C., Wen, S. W., & Fell, D. B. (2019). Health outcomes of young children born to mothers who received 2009 pandemic H1N1 influenza vaccination during pregnancy: Retrospective cohort study. BMJ, 366, l4151.
https://doi.org/10.1016/j.vaccine.2017.03.092
Wilkinson, K., Wei, Y., Szwajcer, A., Rabbani, R., Zarychanski, R., Abou-Setta, A. M., & Mahmud, S. M. (2017). Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis. Vaccine, 35(21), 2775–2780.
https://doi.org/10.1136/bmjopen-2022-066182
Wolfe, D. M., Fell, D., Garritty, C., Hamel, C., Butler, C., Hersi, M., Ahmadzai, N., Rice, D. B., Esmaeilisaraji, L., Michaud, A., Soobiah, C., Ghassemi, M., Khan, P. A., Sinilaite, A., Skidmore, B., Tricco, A. C., Moher, D., & Hutton, B. (2023). Safety of influenza vaccination during pregnancy: A systematic review. BMJ Open,13(9), e066182.
https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
World Health Organization. (2023, Januar 12). Influenza (Seasonal). Fact Sheets.
https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-2025-northern-hemisphere-influenza-season
World Health Organization. (2024, Februar 23). Recommended composition of influenza virus vaccines for use in the 2024-2025 northern hemisphere influenza season. Who.Int.
https://doi.org/10.1111/irv.12969
Zanobini, P., Bonaccorsi, G., Lorini, C., Haag, M., McGovern, I., Paget, J., & Caini, S. (2022). Global patterns of seasonal influenza activity, duration of activity and virus (sub)type circulation from 2010 to 2020. Influenza and Other Respiratory Viruses, 16(4), 696–706.
Alle #IMPFGEFLÜSTER Texte & Videos in voller Länge nur auf Telegram!
🔗 Telegram (https://t.me/Impfgefluester)
🔗 Youtube (http://m.youtube.com/channel/UC88-oRlcI9eoGZMHkz6L4Gg?app=desktop&sub_confirmation=1)
🔗 Twitter (https://twitter.com/Impfgefluester)
🔗 Rumble (https://rumble.com/c/c-2338704)
@Impfgefluester
Eine freiwillige Unterstützung erleichtert es uns, auch weiterhin enormen Zeitaufwand für die Recherchen aufbringen zu können.
Unterstützen könnt ihr uns per Banküberweisung:
FINK
IBAN AT89 2011 1852 6509 9000
Verwendungszweck: Geschenk
Herzlichen Dank!
Vijaykrishna, D., Mukerji, R., & Smith, G. J. D. (2015). RNA Virus Reassortment: An Evolutionary Mechanism for Host Jumps and Immune Evasion. PLoS Pathogens, 11(7), e1004902.
https://doi.org/10.1136/bmj.l4151
Walsh, L. K., Donelle, J., Dodds, L., Hawken, S., Wilson, K., Benchimol, E. I., Chakraborty, P., Guttmann, A., Kwong, J. C., MacDonald, N. E., Ortiz, J. R., Sprague, A. E., Top, K. A., Walker, M. C., Wen, S. W., & Fell, D. B. (2019). Health outcomes of young children born to mothers who received 2009 pandemic H1N1 influenza vaccination during pregnancy: Retrospective cohort study. BMJ, 366, l4151.
https://doi.org/10.1016/j.vaccine.2017.03.092
Wilkinson, K., Wei, Y., Szwajcer, A., Rabbani, R., Zarychanski, R., Abou-Setta, A. M., & Mahmud, S. M. (2017). Efficacy and safety of high-dose influenza vaccine in elderly adults: A systematic review and meta-analysis. Vaccine, 35(21), 2775–2780.
https://doi.org/10.1136/bmjopen-2022-066182
Wolfe, D. M., Fell, D., Garritty, C., Hamel, C., Butler, C., Hersi, M., Ahmadzai, N., Rice, D. B., Esmaeilisaraji, L., Michaud, A., Soobiah, C., Ghassemi, M., Khan, P. A., Sinilaite, A., Skidmore, B., Tricco, A. C., Moher, D., & Hutton, B. (2023). Safety of influenza vaccination during pregnancy: A systematic review. BMJ Open,13(9), e066182.
https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
World Health Organization. (2023, Januar 12). Influenza (Seasonal). Fact Sheets.
https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2024-2025-northern-hemisphere-influenza-season
World Health Organization. (2024, Februar 23). Recommended composition of influenza virus vaccines for use in the 2024-2025 northern hemisphere influenza season. Who.Int.
https://doi.org/10.1111/irv.12969
Zanobini, P., Bonaccorsi, G., Lorini, C., Haag, M., McGovern, I., Paget, J., & Caini, S. (2022). Global patterns of seasonal influenza activity, duration of activity and virus (sub)type circulation from 2010 to 2020. Influenza and Other Respiratory Viruses, 16(4), 696–706.
Alle #IMPFGEFLÜSTER Texte & Videos in voller Länge nur auf Telegram!
🔗 Telegram (https://t.me/Impfgefluester)
🔗 Youtube (http://m.youtube.com/channel/UC88-oRlcI9eoGZMHkz6L4Gg?app=desktop&sub_confirmation=1)
🔗 Twitter (https://twitter.com/Impfgefluester)
🔗 Rumble (https://rumble.com/c/c-2338704)
@Impfgefluester
Eine freiwillige Unterstützung erleichtert es uns, auch weiterhin enormen Zeitaufwand für die Recherchen aufbringen zu können.
Unterstützen könnt ihr uns per Banküberweisung:
FINK
IBAN AT89 2011 1852 6509 9000
Verwendungszweck: Geschenk
Herzlichen Dank!
13.03.202521:08
https://doi.org/10.1186/s12879-023-08541-0
Carregaro, R. L., Roscani, A. N. C. P., Raimundo, A. C. S., Ferreira, L., Vanni, T., da Graça Salomão, M., Probst, L. F., & Viscondi, J. Y. K. (2023). Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: An overview of systematic reviews. BMC Infectious Diseases, 23(1), 563.
https://www.cdc.gov/vaccines/pubs/pinkbook/flu.html
Centers for Disease Control and Prevention. (2021, September 18). Influenza. Pinkbook.
https://doi.org/10.3389/fimmu.2021.711997
Chen, J., Wang, J., Zhang, J., & Ly, H. (2021). Advances in Development and Application of Influenza Vaccines. Frontiers in Immunology, 12, 711997.
https://doi.org/10.1038/s41591-022-01810-6
Choutka, J., Jansari, V., Hornig, M., & Iwasaki, A. (2022). Unexplained post-acute infection syndromes. Nature Medicine, 28(5), Article 5.
https://doi.org/10.1093/infdis/jiad303
Cohen, L. E., Hansen, C. L., Andrew, M. K., McNeil, S. A., Vanhems, P., Kyncl, J., Díez Domingo, J., Zhang, T., Dbaibo, G., Laguna-Torres, V. A., Draganescu, A., Baumeister, E., Gomez, D., Raboni, S. M., Giamberardino, H. I. G., Nunes, M. C., Burtseva, E., Sominina, A., Medić, S., … Chaves, S. S. (2023). Predictors of severity of influenza-related hospitalizations: Results from the Global Influenza Hospital Surveillance Network (GIHSN). The Journal of Infectious Diseases, jiad303.
https://doi.org/10.1111/irv.12504
Coleman, B. L., Fadel, S. A., Fitzpatrick, T., & Thomas, S.-M. (2018). Risk factors for serious outcomes associated with influenza illness in high- versus low- and middle-income countries: Systematic literature review and meta-analysis. Influenza and Other Respiratory Viruses, 12(1), 22–29.
https://doi.org/10.1097/PRA.0000000000000508
Collins, M. L., Cheney, G. A., Yehl, J. L., Sullivan, G. A., Stewart, J. T., & Catalano, G. (2021). Postviral Depression. Journal of Psychiatric Practice, 27(2), 126–130.
https://doi.org/10.1016/j.vaccine.2020.03.034
Cross, J. W., Joy, M., McGee, C., Akinyemi, O., Gatenby, P., & de Lusignan, S. (2020). Adverse events of interest vary by influenza vaccine type and brand: Sentinel network study of eight seasons (2010–2018). Vaccine, 38(22), 3869–3880.
https://doi.org/10.3390/v14071477
da Costa, J. C., Siqueira, M. M., Brown, D., Lopes, J. O., da Costa, B. C., Gama, E. L., & Aguiar-Oliveira, M. de L. (2022). Vaccine Mismatches, Viral Circulation, and Clinical Severity Patterns of Influenza B Victoria and Yamagata Infections in Brazil over the Decade 2010–2020: A Statistical and Phylogeny–Trait Analyses. Viruses, 14(7), 1477.
https://ourworldindata.org/influenza-deaths
Dattani, S., & Spooner, F. (2022, Oktober 20). How many people die from the flu? Our World in Data.
https://doi.org/10.1002/14651858.CD001269.pub6
Demicheli, V., Jefferson, T., Ferroni, E., Rivetti, A., & Pietrantonj, C. D. (2018). Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews, 2.
https://doi.org/10.1002/14651858.CD004876.pub4
Demicheli, V., Jefferson, T., Pietrantonj, C. D., Ferroni, E., Thorning, S., Thomas, R. E., & Rivetti, A. (2018). Vaccines for preventing influenza in the elderly. Cochrane Database of Systematic Reviews, 2.
https://www.aerzteblatt.de/nachrichten/149739/Influenza-B-Yamagata-seit-COVID-19-verschwunden-WHO-modifiziert-vierte-Komponente-des-Impfstoffs
Deutsches Ärzteblatt. (2024, April 3). Influenza B/Yamagata seit COVID-19 verschwunden: WHO modifiziert vierte Komponente des Impfstoffs. aerzteblatt.de.
https://dgk.de/fachleute/dgk-fachnewsletter/grippe-impfstoffe-trivalent-tetravalent-adjuvantiert.html
Deutsches Grünes Kreuz e. V. (2017, Dezember). Grippe-Impfstoffe: Trivalent, tetravalent, adjuvantiert? Deutsches Grünes Kreuz für Gesundheit e.V.
https://doi.org/10.1007/s12098-020-03214-1
Dharmapalan, D. (2020). Influenza. Indian Journal of Pediatrics, 87(10), 828–832.
Carregaro, R. L., Roscani, A. N. C. P., Raimundo, A. C. S., Ferreira, L., Vanni, T., da Graça Salomão, M., Probst, L. F., & Viscondi, J. Y. K. (2023). Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: An overview of systematic reviews. BMC Infectious Diseases, 23(1), 563.
https://www.cdc.gov/vaccines/pubs/pinkbook/flu.html
Centers for Disease Control and Prevention. (2021, September 18). Influenza. Pinkbook.
https://doi.org/10.3389/fimmu.2021.711997
Chen, J., Wang, J., Zhang, J., & Ly, H. (2021). Advances in Development and Application of Influenza Vaccines. Frontiers in Immunology, 12, 711997.
https://doi.org/10.1038/s41591-022-01810-6
Choutka, J., Jansari, V., Hornig, M., & Iwasaki, A. (2022). Unexplained post-acute infection syndromes. Nature Medicine, 28(5), Article 5.
https://doi.org/10.1093/infdis/jiad303
Cohen, L. E., Hansen, C. L., Andrew, M. K., McNeil, S. A., Vanhems, P., Kyncl, J., Díez Domingo, J., Zhang, T., Dbaibo, G., Laguna-Torres, V. A., Draganescu, A., Baumeister, E., Gomez, D., Raboni, S. M., Giamberardino, H. I. G., Nunes, M. C., Burtseva, E., Sominina, A., Medić, S., … Chaves, S. S. (2023). Predictors of severity of influenza-related hospitalizations: Results from the Global Influenza Hospital Surveillance Network (GIHSN). The Journal of Infectious Diseases, jiad303.
https://doi.org/10.1111/irv.12504
Coleman, B. L., Fadel, S. A., Fitzpatrick, T., & Thomas, S.-M. (2018). Risk factors for serious outcomes associated with influenza illness in high- versus low- and middle-income countries: Systematic literature review and meta-analysis. Influenza and Other Respiratory Viruses, 12(1), 22–29.
https://doi.org/10.1097/PRA.0000000000000508
Collins, M. L., Cheney, G. A., Yehl, J. L., Sullivan, G. A., Stewart, J. T., & Catalano, G. (2021). Postviral Depression. Journal of Psychiatric Practice, 27(2), 126–130.
https://doi.org/10.1016/j.vaccine.2020.03.034
Cross, J. W., Joy, M., McGee, C., Akinyemi, O., Gatenby, P., & de Lusignan, S. (2020). Adverse events of interest vary by influenza vaccine type and brand: Sentinel network study of eight seasons (2010–2018). Vaccine, 38(22), 3869–3880.
https://doi.org/10.3390/v14071477
da Costa, J. C., Siqueira, M. M., Brown, D., Lopes, J. O., da Costa, B. C., Gama, E. L., & Aguiar-Oliveira, M. de L. (2022). Vaccine Mismatches, Viral Circulation, and Clinical Severity Patterns of Influenza B Victoria and Yamagata Infections in Brazil over the Decade 2010–2020: A Statistical and Phylogeny–Trait Analyses. Viruses, 14(7), 1477.
https://ourworldindata.org/influenza-deaths
Dattani, S., & Spooner, F. (2022, Oktober 20). How many people die from the flu? Our World in Data.
https://doi.org/10.1002/14651858.CD001269.pub6
Demicheli, V., Jefferson, T., Ferroni, E., Rivetti, A., & Pietrantonj, C. D. (2018). Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews, 2.
https://doi.org/10.1002/14651858.CD004876.pub4
Demicheli, V., Jefferson, T., Pietrantonj, C. D., Ferroni, E., Thorning, S., Thomas, R. E., & Rivetti, A. (2018). Vaccines for preventing influenza in the elderly. Cochrane Database of Systematic Reviews, 2.
https://www.aerzteblatt.de/nachrichten/149739/Influenza-B-Yamagata-seit-COVID-19-verschwunden-WHO-modifiziert-vierte-Komponente-des-Impfstoffs
Deutsches Ärzteblatt. (2024, April 3). Influenza B/Yamagata seit COVID-19 verschwunden: WHO modifiziert vierte Komponente des Impfstoffs. aerzteblatt.de.
https://dgk.de/fachleute/dgk-fachnewsletter/grippe-impfstoffe-trivalent-tetravalent-adjuvantiert.html
Deutsches Grünes Kreuz e. V. (2017, Dezember). Grippe-Impfstoffe: Trivalent, tetravalent, adjuvantiert? Deutsches Grünes Kreuz für Gesundheit e.V.
https://doi.org/10.1007/s12098-020-03214-1
Dharmapalan, D. (2020). Influenza. Indian Journal of Pediatrics, 87(10), 828–832.
26.11.202419:06
https://doi.org/10.1007/978-1-0716-3770-8_7
Vadovics, M., Muramatsu, H., Sárközy, A., & Pardi, N. (2024). Production and Evaluation of Nucleoside-Modified mRNA Vaccines for Infectious Diseases. Methods in Molecular Biology (Clifton, N.J.), 2786, 167–181.
https://doi.org/10.1016/j.vaccine.2004.09.012
Verdier, F., Burnett, R., Michelet-Habchi, C., Moretto, P., Fievet-Groyne, F., & Sauzeat, E. (2005). Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey. Vaccine, 23(11), 1359–1367.
https://doi.org/10.3389/fimmu.2023.1043109
Verma, S. K., Mahajan, P., Singh, N. K., Gupta, A., Aggarwal, R., Rappuoli, R., & Johri, A. K. (2023). New-age vaccine adjuvants, their development, and future perspective. Frontiers in Immunology, 14, 1043109.
https://doi.org/10.1007/s00103-019-02921-1
Wagner, R., & Hildt, E. (2019). Zusammensetzung und Wirkmechanismen von Adjuvanzien in zugelassenen viralen Impfstoffen. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 62(4), 462–471.
https://doi.org/10.1038/nri3862
Wherry, E. J., & Kurachi, M. (2015). Molecular and cellular insights into T cell exhaustion. Nature reviews. Immunology, 15(8), 486–499.
https://doi.org/10.3390/vaccines10081256
Wong, J. C., Lao, C. T., Yousif, M. M., & Luga, J. M. (2022). Fast Tracking-Vaccine Safety, Efficacy, and Lessons Learned: A Narrative Review. Vaccines, 10(8), 1256.
https://www.aerzteblatt.de/archiv/149561/Zielgruppenspezifische-Wahl-des-Impfstoffs-bei-Grippeimpfung
Wutzler, P., Hardt, R., Wahle, K., & Knuf, M. (2013, November 22). Zielgruppenspezifische Wahl des Impfstoffs bei Grippeimpfung. Deutsches Ärzteblatt.
https://doi.org/10.1186/s12985-023-02234-5
Zhang, H., Cai, S., Xia, Y., Lin, Y., Zhou, G., Yu, Y., & Feng, M. (2023). Association between human herpesvirus infection and cervical carcinoma: A systematic review and meta-analysis. Virology Journal, 20(1), 288.
https://doi.org/10.1038/s41392-023-01557-7
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023). Vaccine adjuvants: Mechanisms and platforms. Signal Transduction and Targeted Therapy, 8(1), 1–24.
https://doi.org/10.1080/21645515.2018.1461296
Zheng, Z., Diaz-Arévalo, D., Guan, H., & Zeng, M. (2018). Noninvasive vaccination against infectious diseases. Human Vaccines & Immunotherapeutics, 14(7), 1717–1733.
Alle #IMPFGEFLÜSTER Texte & Videos in voller Länge nur auf Telegram!
🔗 Telegram (https://t.me/Impfgefluester)
🔗 Youtube (http://m.youtube.com/channel/UC88-oRlcI9eoGZMHkz6L4Gg?app=desktop&sub_confirmation=1)
🔗 Twitter (https://twitter.com/Impfgefluester)
🔗 Rumble (https://rumble.com/c/c-2338704)
@Impfgefluester
Eine freiwillige Unterstützung erleichtert es uns, auch weiterhin enormen Zeitaufwand für die Recherchen aufbringen zu können.
Unterstützen könnt ihr uns per Banküberweisung
IBAN AT89 2011 1852 6509 9000
Verwendungszweck: Geschenk
Herzlichen Dank!
Vadovics, M., Muramatsu, H., Sárközy, A., & Pardi, N. (2024). Production and Evaluation of Nucleoside-Modified mRNA Vaccines for Infectious Diseases. Methods in Molecular Biology (Clifton, N.J.), 2786, 167–181.
https://doi.org/10.1016/j.vaccine.2004.09.012
Verdier, F., Burnett, R., Michelet-Habchi, C., Moretto, P., Fievet-Groyne, F., & Sauzeat, E. (2005). Aluminium assay and evaluation of the local reaction at several time points after intramuscular administration of aluminium containing vaccines in the Cynomolgus monkey. Vaccine, 23(11), 1359–1367.
https://doi.org/10.3389/fimmu.2023.1043109
Verma, S. K., Mahajan, P., Singh, N. K., Gupta, A., Aggarwal, R., Rappuoli, R., & Johri, A. K. (2023). New-age vaccine adjuvants, their development, and future perspective. Frontiers in Immunology, 14, 1043109.
https://doi.org/10.1007/s00103-019-02921-1
Wagner, R., & Hildt, E. (2019). Zusammensetzung und Wirkmechanismen von Adjuvanzien in zugelassenen viralen Impfstoffen. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 62(4), 462–471.
https://doi.org/10.1038/nri3862
Wherry, E. J., & Kurachi, M. (2015). Molecular and cellular insights into T cell exhaustion. Nature reviews. Immunology, 15(8), 486–499.
https://doi.org/10.3390/vaccines10081256
Wong, J. C., Lao, C. T., Yousif, M. M., & Luga, J. M. (2022). Fast Tracking-Vaccine Safety, Efficacy, and Lessons Learned: A Narrative Review. Vaccines, 10(8), 1256.
https://www.aerzteblatt.de/archiv/149561/Zielgruppenspezifische-Wahl-des-Impfstoffs-bei-Grippeimpfung
Wutzler, P., Hardt, R., Wahle, K., & Knuf, M. (2013, November 22). Zielgruppenspezifische Wahl des Impfstoffs bei Grippeimpfung. Deutsches Ärzteblatt.
https://doi.org/10.1186/s12985-023-02234-5
Zhang, H., Cai, S., Xia, Y., Lin, Y., Zhou, G., Yu, Y., & Feng, M. (2023). Association between human herpesvirus infection and cervical carcinoma: A systematic review and meta-analysis. Virology Journal, 20(1), 288.
https://doi.org/10.1038/s41392-023-01557-7
Zhao, T., Cai, Y., Jiang, Y., He, X., Wei, Y., Yu, Y., & Tian, X. (2023). Vaccine adjuvants: Mechanisms and platforms. Signal Transduction and Targeted Therapy, 8(1), 1–24.
https://doi.org/10.1080/21645515.2018.1461296
Zheng, Z., Diaz-Arévalo, D., Guan, H., & Zeng, M. (2018). Noninvasive vaccination against infectious diseases. Human Vaccines & Immunotherapeutics, 14(7), 1717–1733.
Alle #IMPFGEFLÜSTER Texte & Videos in voller Länge nur auf Telegram!
🔗 Telegram (https://t.me/Impfgefluester)
🔗 Youtube (http://m.youtube.com/channel/UC88-oRlcI9eoGZMHkz6L4Gg?app=desktop&sub_confirmation=1)
🔗 Twitter (https://twitter.com/Impfgefluester)
🔗 Rumble (https://rumble.com/c/c-2338704)
@Impfgefluester
Eine freiwillige Unterstützung erleichtert es uns, auch weiterhin enormen Zeitaufwand für die Recherchen aufbringen zu können.
Unterstützen könnt ihr uns per Banküberweisung
IBAN AT89 2011 1852 6509 9000
Verwendungszweck: Geschenk
Herzlichen Dank!
03.04.202518:15
#IMPFGEFLUESTER Linksammlung Specials
Liebe Impfgeflüster Fans!
Anbei die Linksammlung unserer bisher veröffentlichten Specials!
Demnächst wird unsere 6. Staffel starten. Wieder mit vielen hochinteressanten Studienergebnissen, die natürlich vom Mainstream nicht aufgegriffen wurden!
LG Ihr Impfgeflüster Team
___________
Special 2024-07 - Sommer-Special
https://t.me/Impfgefluester/350
Abgetriebene Fötenzellen in Impfstoffen?
Das kleine Mädchen hinter der Zell-Linie HEK-293...
Der kleine Bub hinter der Zell- Linie MRC-5...
Kommt die Wahrheit ans Licht?
___________
Special 2024-11 - Herbst-Winter Special 2024
https://t.me/Impfgefluester/371
Adjuvantien in Impfstoffen?
Ist das Neurotoxin Aluminium der richtige Weg?
Nebenwirkungen und Sicherheit korrekt nachgewiesen?
___________
Special 2025-03 - Winter-Special 2025
https://t.me/Impfgefluester/387
Die unbequeme Wahrheit über die Grippe-Impfung.
Nützt es nichts, schadet es ja nicht.
Aber stimmt das wirklich?
___________
Alle #IMPFGEFLÜSTER Texte & Videos in voller Länge nur auf Telegram!
🔗 Telegram
🔗 Youtube
🔗 Twitter
🔗 Rumble
@Impfgefluester
Liebe Impfgeflüster Fans!
Anbei die Linksammlung unserer bisher veröffentlichten Specials!
Demnächst wird unsere 6. Staffel starten. Wieder mit vielen hochinteressanten Studienergebnissen, die natürlich vom Mainstream nicht aufgegriffen wurden!
LG Ihr Impfgeflüster Team
___________
Special 2024-07 - Sommer-Special
https://t.me/Impfgefluester/350
Abgetriebene Fötenzellen in Impfstoffen?
Das kleine Mädchen hinter der Zell-Linie HEK-293...
Der kleine Bub hinter der Zell- Linie MRC-5...
Kommt die Wahrheit ans Licht?
___________
Special 2024-11 - Herbst-Winter Special 2024
https://t.me/Impfgefluester/371
Adjuvantien in Impfstoffen?
Ist das Neurotoxin Aluminium der richtige Weg?
Nebenwirkungen und Sicherheit korrekt nachgewiesen?
___________
Special 2025-03 - Winter-Special 2025
https://t.me/Impfgefluester/387
Die unbequeme Wahrheit über die Grippe-Impfung.
Nützt es nichts, schadet es ja nicht.
Aber stimmt das wirklich?
___________
Alle #IMPFGEFLÜSTER Texte & Videos in voller Länge nur auf Telegram!
🔗 Telegram
🔗 Youtube
🔗 Rumble
@Impfgefluester
13.03.202521:08
https://doi.org/10.1002/rmv.2329
O Murchu, E., Comber, L., Jordan, K., Hawkshaw, S., Marshall, L., O’Neill, M., Ryan, M., Teljeur, C., Carnahan, A., Pérez, J. J., Robertson, A. H., Johansen, K., Jonge, J. de, Krause, T., Nicolay, N., Nohynek, H., Pavlopoulou, I., Pebody, R., Penttinen, P., … Harrington, P. (2023a). Systematic review of the efficacy, effectiveness and safety of MF59® adjuvanted seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age. Reviews in Medical Virology, 33(3), e2329.
https://doi.org/10.1002/rmv.2331
O Murchu, E., Comber, L., Jordan, K., Hawkshaw, S., Marshall, L., O’Neill, M., Ryan, M., Teljeur, C., Carnahan, A., Pérez, J. J., Robertson, A. H., Johansen, K., Jonge, J. de, Krause, T., Nicolay, N., Nohynek, H., Pavlopoulou, I., Pebody, R., Penttinen, P., … Harrington, P. (2023b). Systematic review of the efficacy, effectiveness and safety of recombinant haemagglutinin seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age. Reviews in Medical Virology, 33(3), e2331.
https://doi.org/10.1016/S1473-3099(11)70295-X
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012). Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis. The Lancet. Infectious Diseases, 12(1), 36–44.
https://ourworldindata.org/grapher/child-death-rates-by-cause
Our World in Data. (2019). Child mortality rate by cause. Ourworldindata.Org.
https://www.pei.de/DE/arzneimittel/impfstoffe/influenza-grippe/influenza-node.html
Patrozou, E., & Mermel, L. A. (2009). Does Influenza Transmission Occur from Asymptomatic Infection or Prior to Symptom Onset? Public Health Reports, 124(2), 193–196.
Paul-Ehrlich-Institut. (2023, Juli 13). Saisonale Influenza-Impfstoffe. Arzneimittel – Impfstoffe.
https://www.pei.de/EN/newsroom/hp-news/2023/230926-influenza-season-2023-2024-vaccine-doses-released.html#
Paul-Ehrlich-Institut. (2023, September 26). Influenza Season 2023/2024—20.2 Million Doses of Flu Vaccine Already Released. PEI Newsroom.
https://doi.org/10.1080/14787210.2016.1227701
Principi, N., & Esposito, S. (2016). Severe influenza in children: Incidence and risk factors. Expert Review of Anti-Infective Therapy, 14(10), 961–968.
https://doi.org/10.1186/s12879-019-4621-z
Puzelli, S., Di Martino, A., Facchini, M., Fabiani, C., Calzoletti, L., Di Mario, G., Palmieri, A., Affanni, P., Camilloni, B., Chironna, M., D’Agaro, P., Giannecchini, S., Pariani, E., Serra, C., Rizzo, C., Bella, A., Donatelli, I., Castrucci, M. R., & Italian Influenza Laboratory Network. (2019). Co-circulation of the two influenza B lineages during 13 consecutive influenza surveillance seasons in Italy, 2004-2017. BMC Infectious Diseases, 19(1), 990.
https://de.statista.com/statistik/daten/studie/1226353/umfrage/inzidenz-von-influenza-in-deutschland/
Radtke, R. (2024a). Inzidenz gemeldeter Fälle von Influenza („Grippe“) in Deutschland in den Jahren 2001 bis 2024. Statista.
https://de.statista.com/statistik/daten/studie/807491/umfrage/grippewelle-faelle-von-influenza-nach-art-der-viren/
Radtke, R. (2024b). Wöchentliche Anzahl von Influenza-Fällen in Deutschland nach Art der Viren in den Grippesaisons 2021 bis 2023. Statista.
https://www.rki.de/SharedDocs/FAQ/Pandemieplanung/FAQ_Liste_Pandemieplanung.html?nn=12643086
Robert Koch-Institut. (2016, Dezember 5). Antworten auf häufig gestellte Fragen zu Pandemieplanung. Preparedness and Response.
https://www.rki.de/DE/Content/Infekt/NRZ/EM/Aufnahmen/EM_Tab_Influenza.html
Robert Koch-Institut. (2017, Januar 18). Influenzavirus. EM-Aufnahmen.
https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Influenza_saisonal.html
Robert Koch-Institut. (2018, Januar 19). Influenza (Teil 1): Erkrankungen durch saisonale Influenzaviren. RKI-Ratgeber.
https://influenza.rki.de/Saisonberichte/2018.pdf
Robert Koch-Institut. (2019). Bericht zur Epidemiologie der Influenza in Deutschland Saison 2018/19. Arbeitsgemeinschaft Influenza.
O Murchu, E., Comber, L., Jordan, K., Hawkshaw, S., Marshall, L., O’Neill, M., Ryan, M., Teljeur, C., Carnahan, A., Pérez, J. J., Robertson, A. H., Johansen, K., Jonge, J. de, Krause, T., Nicolay, N., Nohynek, H., Pavlopoulou, I., Pebody, R., Penttinen, P., … Harrington, P. (2023a). Systematic review of the efficacy, effectiveness and safety of MF59® adjuvanted seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age. Reviews in Medical Virology, 33(3), e2329.
https://doi.org/10.1002/rmv.2331
O Murchu, E., Comber, L., Jordan, K., Hawkshaw, S., Marshall, L., O’Neill, M., Ryan, M., Teljeur, C., Carnahan, A., Pérez, J. J., Robertson, A. H., Johansen, K., Jonge, J. de, Krause, T., Nicolay, N., Nohynek, H., Pavlopoulou, I., Pebody, R., Penttinen, P., … Harrington, P. (2023b). Systematic review of the efficacy, effectiveness and safety of recombinant haemagglutinin seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age. Reviews in Medical Virology, 33(3), e2331.
https://doi.org/10.1016/S1473-3099(11)70295-X
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012). Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis. The Lancet. Infectious Diseases, 12(1), 36–44.
https://ourworldindata.org/grapher/child-death-rates-by-cause
Our World in Data. (2019). Child mortality rate by cause. Ourworldindata.Org.
https://www.pei.de/DE/arzneimittel/impfstoffe/influenza-grippe/influenza-node.html
Patrozou, E., & Mermel, L. A. (2009). Does Influenza Transmission Occur from Asymptomatic Infection or Prior to Symptom Onset? Public Health Reports, 124(2), 193–196.
Paul-Ehrlich-Institut. (2023, Juli 13). Saisonale Influenza-Impfstoffe. Arzneimittel – Impfstoffe.
https://www.pei.de/EN/newsroom/hp-news/2023/230926-influenza-season-2023-2024-vaccine-doses-released.html#
Paul-Ehrlich-Institut. (2023, September 26). Influenza Season 2023/2024—20.2 Million Doses of Flu Vaccine Already Released. PEI Newsroom.
https://doi.org/10.1080/14787210.2016.1227701
Principi, N., & Esposito, S. (2016). Severe influenza in children: Incidence and risk factors. Expert Review of Anti-Infective Therapy, 14(10), 961–968.
https://doi.org/10.1186/s12879-019-4621-z
Puzelli, S., Di Martino, A., Facchini, M., Fabiani, C., Calzoletti, L., Di Mario, G., Palmieri, A., Affanni, P., Camilloni, B., Chironna, M., D’Agaro, P., Giannecchini, S., Pariani, E., Serra, C., Rizzo, C., Bella, A., Donatelli, I., Castrucci, M. R., & Italian Influenza Laboratory Network. (2019). Co-circulation of the two influenza B lineages during 13 consecutive influenza surveillance seasons in Italy, 2004-2017. BMC Infectious Diseases, 19(1), 990.
https://de.statista.com/statistik/daten/studie/1226353/umfrage/inzidenz-von-influenza-in-deutschland/
Radtke, R. (2024a). Inzidenz gemeldeter Fälle von Influenza („Grippe“) in Deutschland in den Jahren 2001 bis 2024. Statista.
https://de.statista.com/statistik/daten/studie/807491/umfrage/grippewelle-faelle-von-influenza-nach-art-der-viren/
Radtke, R. (2024b). Wöchentliche Anzahl von Influenza-Fällen in Deutschland nach Art der Viren in den Grippesaisons 2021 bis 2023. Statista.
https://www.rki.de/SharedDocs/FAQ/Pandemieplanung/FAQ_Liste_Pandemieplanung.html?nn=12643086
Robert Koch-Institut. (2016, Dezember 5). Antworten auf häufig gestellte Fragen zu Pandemieplanung. Preparedness and Response.
https://www.rki.de/DE/Content/Infekt/NRZ/EM/Aufnahmen/EM_Tab_Influenza.html
Robert Koch-Institut. (2017, Januar 18). Influenzavirus. EM-Aufnahmen.
https://www.rki.de/DE/Content/Infekt/EpidBull/Merkblaetter/Ratgeber_Influenza_saisonal.html
Robert Koch-Institut. (2018, Januar 19). Influenza (Teil 1): Erkrankungen durch saisonale Influenzaviren. RKI-Ratgeber.
https://influenza.rki.de/Saisonberichte/2018.pdf
Robert Koch-Institut. (2019). Bericht zur Epidemiologie der Influenza in Deutschland Saison 2018/19. Arbeitsgemeinschaft Influenza.
13.03.202521:08
https://pubmed.ncbi.nlm.nih.gov/22525386
Joshi AY, Iyer VN, Hartz MF, Patel AM, Li JT. Effectiveness of trivalent inactivated influenza vaccine in influenza-related hospitalization in children: a case-control study. Allergy Asthma Proc. 2012 Mar-Apr;33(2):e23-7.
https://physiciansforinformedconsent.org/immunocompromised-schoolchildren/rgis
Ohmit SE, Petrie JG, Malosh RE, Cowling BJ, Thompson MG, Shay DK, Monto AS. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis. 2013 May;56(10):1363.
Physicians for Informed Consent. Newport Beach (CA): Physicians for Informed Consent. Vaccines: what about immunocompromised schoolchildren? Dec 2019.
https://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm
Centers for Disease Control and Prevention. Washington, D.C.: U.S. Department of Health and Human Services. CDC seasonal flu vaccine effectiveness studies; [cited 2020 Apr 17].
https://www.cdc.gov/flu/about/viruses/change.htm
Centers for Disease Control and Prevention. Washington, D.C.: U.S. Department of Health and Human Services. How the flu virus can change: ‘drift’ and ‘shift’; [cited 2020 Aug 17].
https://www.cdc.gov/flu/vaccines-work/effectivenessqa.htm
Centers for Disease Control and Prevention. Washington, D.C.: U.S. Department of Health and Human Services. How flu vaccine effectiveness and efficacy are measured; [cited 2020 May 14].
https://pubmed.ncbi.nlm.nih.gov/28562111
Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G. Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert Rev Vaccines. 2017 Jul;16(7):723,733.
https://wonder.cdc.gov/ucd-icd10.html
Centers for Disease Control and Prevention. Washington, D.C.: U.S. Department of Health and Human Services. CDC wonder: about underlying cause of death, 1999-2018; [cited 2020 May 2].
https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5306a1.htm
query for death from influenza, 2000-2003. Between 2000 and 2003, there were 61 annual deaths from influenza out of 77 million children age 18 and younger, about 1 death in 1.26 million.
Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB; Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2004 May 28;53(RR-6):1-40.
https://pubmed.ncbi.nlm.nih.gov/15710788
Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med. 2005 Feb 14;165(3):265-72.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005187.pub5/full
Thomas RE, Jefferson T, Lasserson TJ. Influenza vaccination for healthcare workers who care for people aged 60 or older living in long-term care institutions. Cochrane Database Syst Rev. 2016 Jun 2;(6):CD005187.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1626345
Jefferson T. Influenza vaccination: policy versus evidence. BMJ. 2006 Oct 28;333(7574):912-5
https://doi.org/10.1126/science.abm0271
Archer, M. I. (1987). The post-viral : A review. The Journal of the Royal College of General Practitioners, 37(298), 212–214.
Arevalo, C. P., Bolton, M. J., Le Sage, V., Ye, N., Furey, C., Muramatsu, H., Alameh, M.-G., Pardi, N., Drapeau, E. M., Parkhouse, K., Garretson, T., Morris, J. S., Moncla, L. H., Tam, Y. K., Fan, S. H. Y., Lakdawala, S. S., Weissman, D., & Hensley, S. E. (2022). A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science (New York, N.Y.), 378(6622), 899–904.
https://www.arznei-telegramm.de/html/2008_10/0810101_01.html
Arznei-Telegramm. (2008). Wird die Wirksamkeit der Influenzaimpfung überschätzt? arznei-telegramm.de.
https://doi.org/10.1111/eci.14286
Barosa, M., Ioannidis, J. P. A., & Prasad, V. (2024). Evidence base for yearly respiratory virus vaccines: Current status and proposed improved strategies. European Journal of Clinical Investigation, 54(10), e14286.
Joshi AY, Iyer VN, Hartz MF, Patel AM, Li JT. Effectiveness of trivalent inactivated influenza vaccine in influenza-related hospitalization in children: a case-control study. Allergy Asthma Proc. 2012 Mar-Apr;33(2):e23-7.
https://physiciansforinformedconsent.org/immunocompromised-schoolchildren/rgis
Ohmit SE, Petrie JG, Malosh RE, Cowling BJ, Thompson MG, Shay DK, Monto AS. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis. 2013 May;56(10):1363.
Physicians for Informed Consent. Newport Beach (CA): Physicians for Informed Consent. Vaccines: what about immunocompromised schoolchildren? Dec 2019.
https://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm
Centers for Disease Control and Prevention. Washington, D.C.: U.S. Department of Health and Human Services. CDC seasonal flu vaccine effectiveness studies; [cited 2020 Apr 17].
https://www.cdc.gov/flu/about/viruses/change.htm
Centers for Disease Control and Prevention. Washington, D.C.: U.S. Department of Health and Human Services. How the flu virus can change: ‘drift’ and ‘shift’; [cited 2020 Aug 17].
https://www.cdc.gov/flu/vaccines-work/effectivenessqa.htm
Centers for Disease Control and Prevention. Washington, D.C.: U.S. Department of Health and Human Services. How flu vaccine effectiveness and efficacy are measured; [cited 2020 May 14].
https://pubmed.ncbi.nlm.nih.gov/28562111
Belongia EA, Skowronski DM, McLean HQ, Chambers C, Sundaram ME, De Serres G. Repeated annual influenza vaccination and vaccine effectiveness: review of evidence. Expert Rev Vaccines. 2017 Jul;16(7):723,733.
https://wonder.cdc.gov/ucd-icd10.html
Centers for Disease Control and Prevention. Washington, D.C.: U.S. Department of Health and Human Services. CDC wonder: about underlying cause of death, 1999-2018; [cited 2020 May 2].
https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5306a1.htm
query for death from influenza, 2000-2003. Between 2000 and 2003, there were 61 annual deaths from influenza out of 77 million children age 18 and younger, about 1 death in 1.26 million.
Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB; Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2004 May 28;53(RR-6):1-40.
https://pubmed.ncbi.nlm.nih.gov/15710788
Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med. 2005 Feb 14;165(3):265-72.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005187.pub5/full
Thomas RE, Jefferson T, Lasserson TJ. Influenza vaccination for healthcare workers who care for people aged 60 or older living in long-term care institutions. Cochrane Database Syst Rev. 2016 Jun 2;(6):CD005187.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1626345
Jefferson T. Influenza vaccination: policy versus evidence. BMJ. 2006 Oct 28;333(7574):912-5
https://doi.org/10.1126/science.abm0271
Archer, M. I. (1987). The post-viral : A review. The Journal of the Royal College of General Practitioners, 37(298), 212–214.
Arevalo, C. P., Bolton, M. J., Le Sage, V., Ye, N., Furey, C., Muramatsu, H., Alameh, M.-G., Pardi, N., Drapeau, E. M., Parkhouse, K., Garretson, T., Morris, J. S., Moncla, L. H., Tam, Y. K., Fan, S. H. Y., Lakdawala, S. S., Weissman, D., & Hensley, S. E. (2022). A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science (New York, N.Y.), 378(6622), 899–904.
https://www.arznei-telegramm.de/html/2008_10/0810101_01.html
Arznei-Telegramm. (2008). Wird die Wirksamkeit der Influenzaimpfung überschätzt? arznei-telegramm.de.
https://doi.org/10.1111/eci.14286
Barosa, M., Ioannidis, J. P. A., & Prasad, V. (2024). Evidence base for yearly respiratory virus vaccines: Current status and proposed improved strategies. European Journal of Clinical Investigation, 54(10), e14286.
13.03.202521:08
https://influenza.rki.de/Wochenberichte/2021_2022/2022-39.pdf
Robert Koch-Institut. (2022, Oktober). ARE-Wochenbericht des RKI – 39. KW (26.9. Bis 2.10.2022). Aktuelles zu akuten respiratorischen Erkrankungen.
https://www.rki.de/SharedDocs/FAQ/Impfen/Influenza/FAQ_Uebersicht.html
Robert Koch-Institut. (2023a, September 18). Antworten auf häufig gestellte Fragen zur Schutzimpfung gegen Influenza. Infektionskrankheiten A-Z.
https://www.rki.de/SharedDocs/FAQ/Influenza/FAQ_Liste.html
Robert Koch-Institut. (2023b, September 18). Häufig gestellte Fragen und Antworten zur Grippe. Infektionskrankheiten A-Z.
https://influenza.rki.de/Wochenberichte/2022_2023/2023-38.pdf
Robert Koch-Institut. (2023c, Oktober). ARE-Wochenbericht des RKI – 38. KW (18.9. Bis 24.9.2023). Aktuelles zu akuten respiratorischen Erkrankungen.
https://www.rki.de/DE/Content/Infekt/Impfen/Forschungsprojekte/OKaPII/Ergebnisbericht_2024.html
Robert Koch-Institut. (2024a, August 22). Ergebnisbericht 2024: OKaPII - Onlinebefragung von Klinikpersonal zur Influenza-Impfung. Forschungsprojekte.
https://www.rki.de/SharedDocs/FAQ/Impfen/Influenza/FAQ_Uebersicht.html
Robert Koch-Institut. (2024b, September 16). Antworten auf häufig gestellte Fragen zur Schutzimpfung gegen Influenza. Infektionskrankheiten A-Z.
https://influenza.rki.de/Wochenberichte/2023_2024/2024-15.pdf
Robert Koch-Institut. (2024c, April). ARE-Wochenbericht des RKI. Aktuelles zu akuten respiratorischen Erkrankungen 15. Kalenderwoche (8.4. bis 14.4.2024).
https://doi.org/10.1007/s15010-020-01529-x
Rößler, S., Ankert, J., Baier, M., Pletz, M. W., & Hagel, S. (2021). Influenza-associated in-hospital mortality during the 2017/2018 influenza season: A retrospective multicentre cohort study in central Germany. Infection, 49(1), 149–152.
https://doi.org/10.1097/MCC.0000000000000638
Sarda, C., Palma, P., & Rello, J. (2019). Severe influenza: Overview in critically ill patients. Current Opinion in Critical Care, 25(5), 449–457.
https://doi.org/10.1111/irv.12470
Sellers, S. A., Hagan, R. S., Hayden, F. G., & Fischer, W. A. (2017). The hidden burden of influenza: A review of the extra-pulmonary complications of influenza infection. Influenza and Other Respiratory Viruses, 11(5), 372–393.
https://doi.org/10.1080/21645515.2017.1343226
Smetana, J., Chlibek, R., Shaw, J., Splino, M., & Prymula, R. (2017). Influenza vaccination in the elderly. Human Vaccines & Immunotherapeutics, 14(3), 540–549.
https://doi.org/10.1186/1471-2334-11-233
Streng, A., Grote, V., & Liese, J. G. (2011). Severe influenza cases in paediatric intensive care units in Germany during the pre-pandemic seasons 2005 to 2008. BMC Infectious Diseases, 11, 233.
https://doi.org/10.1542/peds.2017-3310
Sukumaran, L., McCarthy, N. L., Kharbanda, E. O., Vazquez-Benitez, G., Lipkind, H. S., Jackson, L., Klein, N. P., Naleway, A. L., McClure, D. L., Hechter, R. C., Kawai, A. T., Glanz, J. M., & Weintraub, E. S. (2018). Infant Hospitalizations and Mortality After Maternal Vaccination. Pediatrics, 141(3), e20173310.
https://doi.org/10.1002/14651858.CD005187.pub4
Thomas, R. E., Jefferson, T., & Lasserson, T. J. (2013). Influenza vaccination for healthcare workers who care for people aged 60 or older living in long‐term care institutions. Cochrane Database of Systematic Reviews, 7.
https://doi.org/10.1186/1741-7015-11-153
Tricco, A. C., Chit, A., Soobiah, C., Hallett, D., Meier, G., Chen, M. H., Tashkandi, M., Bauch, C. T., & Loeb, M. (2013). Comparing influenza vaccine efficacy against mismatched and matched strains: A systematic review and meta-analysis. BMC Medicine, 11, 153.
https://doi.org/10.1016/j.vaccine.2023.03.066
Uemura, K., Ono, S., Michihata, N., Yamana, H., & Yasunaga, H. (2023). Duration of influenza vaccine effectiveness in the elderly in Japan: A retrospective cohort study using large-scale population-based registry data. Vaccine, 41(19), 3092–3098.
Robert Koch-Institut. (2022, Oktober). ARE-Wochenbericht des RKI – 39. KW (26.9. Bis 2.10.2022). Aktuelles zu akuten respiratorischen Erkrankungen.
https://www.rki.de/SharedDocs/FAQ/Impfen/Influenza/FAQ_Uebersicht.html
Robert Koch-Institut. (2023a, September 18). Antworten auf häufig gestellte Fragen zur Schutzimpfung gegen Influenza. Infektionskrankheiten A-Z.
https://www.rki.de/SharedDocs/FAQ/Influenza/FAQ_Liste.html
Robert Koch-Institut. (2023b, September 18). Häufig gestellte Fragen und Antworten zur Grippe. Infektionskrankheiten A-Z.
https://influenza.rki.de/Wochenberichte/2022_2023/2023-38.pdf
Robert Koch-Institut. (2023c, Oktober). ARE-Wochenbericht des RKI – 38. KW (18.9. Bis 24.9.2023). Aktuelles zu akuten respiratorischen Erkrankungen.
https://www.rki.de/DE/Content/Infekt/Impfen/Forschungsprojekte/OKaPII/Ergebnisbericht_2024.html
Robert Koch-Institut. (2024a, August 22). Ergebnisbericht 2024: OKaPII - Onlinebefragung von Klinikpersonal zur Influenza-Impfung. Forschungsprojekte.
https://www.rki.de/SharedDocs/FAQ/Impfen/Influenza/FAQ_Uebersicht.html
Robert Koch-Institut. (2024b, September 16). Antworten auf häufig gestellte Fragen zur Schutzimpfung gegen Influenza. Infektionskrankheiten A-Z.
https://influenza.rki.de/Wochenberichte/2023_2024/2024-15.pdf
Robert Koch-Institut. (2024c, April). ARE-Wochenbericht des RKI. Aktuelles zu akuten respiratorischen Erkrankungen 15. Kalenderwoche (8.4. bis 14.4.2024).
https://doi.org/10.1007/s15010-020-01529-x
Rößler, S., Ankert, J., Baier, M., Pletz, M. W., & Hagel, S. (2021). Influenza-associated in-hospital mortality during the 2017/2018 influenza season: A retrospective multicentre cohort study in central Germany. Infection, 49(1), 149–152.
https://doi.org/10.1097/MCC.0000000000000638
Sarda, C., Palma, P., & Rello, J. (2019). Severe influenza: Overview in critically ill patients. Current Opinion in Critical Care, 25(5), 449–457.
https://doi.org/10.1111/irv.12470
Sellers, S. A., Hagan, R. S., Hayden, F. G., & Fischer, W. A. (2017). The hidden burden of influenza: A review of the extra-pulmonary complications of influenza infection. Influenza and Other Respiratory Viruses, 11(5), 372–393.
https://doi.org/10.1080/21645515.2017.1343226
Smetana, J., Chlibek, R., Shaw, J., Splino, M., & Prymula, R. (2017). Influenza vaccination in the elderly. Human Vaccines & Immunotherapeutics, 14(3), 540–549.
https://doi.org/10.1186/1471-2334-11-233
Streng, A., Grote, V., & Liese, J. G. (2011). Severe influenza cases in paediatric intensive care units in Germany during the pre-pandemic seasons 2005 to 2008. BMC Infectious Diseases, 11, 233.
https://doi.org/10.1542/peds.2017-3310
Sukumaran, L., McCarthy, N. L., Kharbanda, E. O., Vazquez-Benitez, G., Lipkind, H. S., Jackson, L., Klein, N. P., Naleway, A. L., McClure, D. L., Hechter, R. C., Kawai, A. T., Glanz, J. M., & Weintraub, E. S. (2018). Infant Hospitalizations and Mortality After Maternal Vaccination. Pediatrics, 141(3), e20173310.
https://doi.org/10.1002/14651858.CD005187.pub4
Thomas, R. E., Jefferson, T., & Lasserson, T. J. (2013). Influenza vaccination for healthcare workers who care for people aged 60 or older living in long‐term care institutions. Cochrane Database of Systematic Reviews, 7.
https://doi.org/10.1186/1741-7015-11-153
Tricco, A. C., Chit, A., Soobiah, C., Hallett, D., Meier, G., Chen, M. H., Tashkandi, M., Bauch, C. T., & Loeb, M. (2013). Comparing influenza vaccine efficacy against mismatched and matched strains: A systematic review and meta-analysis. BMC Medicine, 11, 153.
https://doi.org/10.1016/j.vaccine.2023.03.066
Uemura, K., Ono, S., Michihata, N., Yamana, H., & Yasunaga, H. (2023). Duration of influenza vaccine effectiveness in the elderly in Japan: A retrospective cohort study using large-scale population-based registry data. Vaccine, 41(19), 3092–3098.
13.03.202521:08
https://doi.org/10.1016/j.vaccine.2024.02.059
Guo, J., Chen, X., Guo, Y., Liu, M., Li, P., Tao, Y., Liu, Z., Yang, Z., Zhan, S., & Sun, F. (2024). Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: A systematic review, meta-analysis and meta-regression of test-negative design studies. Vaccine, 42(8), 1883–1891.
https://doi.org/10.4103/jfmpc.jfmpc_856_19
Hadakshi, R. K., Patel, D. M., Patel, M. V., Patel, M. M., Patel, P. J., Patel, M. V., Yadav, K. S., Mahadeviya, H. J., Gajjar, R. A., Patel, P. N., & Patel, H. D. (2020). Association between socioeconomic status and influenza-like illness: A study from Western part of India. Journal of Family Medicine and Primary Care, 9(9), 4587–4591.
https://doi.org/10.3389/fcimb.2020.563850
Hartshorn, K. L. (2020). Innate Immunity and Influenza A Virus Pathogenesis: Lessons for COVID-19. Frontiers in Cellular and Infection Microbiology, 10, 563850.
https://doi.org/10.1001/jamanetworkopen.2022.22241
Hause, A. M., Zhang, B., Yue, X., Marquez, P., Myers, T. R., Parker, C., Gee, J., Su, J., Shimabukuro, T. T., & Shay, D. K. (2022). Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US. JAMA Network Open, 5(7), e2222241.
https://doi.org/10.1016/S2213-2600(14)70034-7
Hayward, A. C., Fragaszy, E. B., Bermingham, A., Wang, L., Copas, A., Edmunds, W. J., Ferguson, N., Goonetilleke, N., Harvey, G., Kovar, J., Lim, M. S. C., McMichael, A., Millett, E. R. C., Nguyen-Van-Tam, J. S., Nazareth, I., Pebody, R., Tabassum, F., Watson, J. M., Wurie, F. B., … Zambon, M. (2014). Comparative community burden and severity of seasonal and pandemic influenza: Results of the Flu Watch cohort study. The Lancet. Respiratory Medicine, 2(6), 445–454.
https://doi.org/10.1093/cid/ciu664
Heikkinen, T., Ikonen, N., & Ziegler, T. (2014). Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999-2012. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 59(11), 1519–1524.
https://doi.org/10.3390/cells10082134
Hirschenberger, M., Hunszinger, V., & Sparrer, K. M. J. (2021). Implications of Innate Immunity in Post-Acute Sequelae of Non-Persistent Viral Infections. Cells, 10(8), 2134.
https://www.pharmazeutische-zeitung.de/naechster-covid-19-impfstoff-mit-drei-vorteilen-146432/
Hohmann-Jeddi, C. (2024, März 26). Moderna-Studie: Nächster Covid-19-Impfstoff mit drei Vorteilen. Pharmazeutische Zeitung.
https://doi.org/10.1002/14651858.CD006207.pub6
Jefferson, T., Dooley, L., Ferroni, E., Al-Ansary, L. A., Driel, M. L. van, Bawazeer, G. A., Jones, M. A., Hoffmann, T. C., Clark, J., Beller, E. M., Glasziou, P. P., & Conly, J. M. (2023). Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database of Systematic Reviews, 1.
https://doi.org/10.1002/14651858.CD004879.pub5
Jefferson, T., Rivetti, A., Pietrantonj, C. D., & Demicheli, V. (2018). Vaccines for preventing influenza in healthy children. Cochrane Database of Systematic Reviews, 2.
https://doi.org/10.1371/journal.pone.0220910
Jeong, S., Jang, E. J., Jo, J., & Jang, S. (2019). Effects of maternal influenza vaccination on adverse birth outcomes: A systematic review and Bayesian meta-analysis. PLoS ONE, 14(8), e0220910.
http://www.ncbi.nlm.nih.gov/books/NBK537197/
Kalarikkal, S. M., & Jaishankar, G. B. (2023). Influenza Vaccine. In StatPearls. StatPearls Publishing.
https://doi.org/10.1093/ofid/ofac664
Kim, P., Coleman, B., Kwong, J. C., Plevneshi, A., Hassan, K., Green, K., McNeil, S. A., Armstrong, I., Gold, W. L., Gubbay, J., Katz, K., Kuster, S. P., Lovinsky, R., Matukas, L., Ostrowska, K., Richardson, D., & McGeer, A. (2023). Burden of Severe Illness Associated With Laboratory-Confirmed Influenza in Adults Aged 50-64 Years, 2010-2011 to 2016-2017. Open Forum Infectious Diseases, 10(1), ofac664.
Guo, J., Chen, X., Guo, Y., Liu, M., Li, P., Tao, Y., Liu, Z., Yang, Z., Zhan, S., & Sun, F. (2024). Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: A systematic review, meta-analysis and meta-regression of test-negative design studies. Vaccine, 42(8), 1883–1891.
https://doi.org/10.4103/jfmpc.jfmpc_856_19
Hadakshi, R. K., Patel, D. M., Patel, M. V., Patel, M. M., Patel, P. J., Patel, M. V., Yadav, K. S., Mahadeviya, H. J., Gajjar, R. A., Patel, P. N., & Patel, H. D. (2020). Association between socioeconomic status and influenza-like illness: A study from Western part of India. Journal of Family Medicine and Primary Care, 9(9), 4587–4591.
https://doi.org/10.3389/fcimb.2020.563850
Hartshorn, K. L. (2020). Innate Immunity and Influenza A Virus Pathogenesis: Lessons for COVID-19. Frontiers in Cellular and Infection Microbiology, 10, 563850.
https://doi.org/10.1001/jamanetworkopen.2022.22241
Hause, A. M., Zhang, B., Yue, X., Marquez, P., Myers, T. R., Parker, C., Gee, J., Su, J., Shimabukuro, T. T., & Shay, D. K. (2022). Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US. JAMA Network Open, 5(7), e2222241.
https://doi.org/10.1016/S2213-2600(14)70034-7
Hayward, A. C., Fragaszy, E. B., Bermingham, A., Wang, L., Copas, A., Edmunds, W. J., Ferguson, N., Goonetilleke, N., Harvey, G., Kovar, J., Lim, M. S. C., McMichael, A., Millett, E. R. C., Nguyen-Van-Tam, J. S., Nazareth, I., Pebody, R., Tabassum, F., Watson, J. M., Wurie, F. B., … Zambon, M. (2014). Comparative community burden and severity of seasonal and pandemic influenza: Results of the Flu Watch cohort study. The Lancet. Respiratory Medicine, 2(6), 445–454.
https://doi.org/10.1093/cid/ciu664
Heikkinen, T., Ikonen, N., & Ziegler, T. (2014). Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999-2012. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America, 59(11), 1519–1524.
https://doi.org/10.3390/cells10082134
Hirschenberger, M., Hunszinger, V., & Sparrer, K. M. J. (2021). Implications of Innate Immunity in Post-Acute Sequelae of Non-Persistent Viral Infections. Cells, 10(8), 2134.
https://www.pharmazeutische-zeitung.de/naechster-covid-19-impfstoff-mit-drei-vorteilen-146432/
Hohmann-Jeddi, C. (2024, März 26). Moderna-Studie: Nächster Covid-19-Impfstoff mit drei Vorteilen. Pharmazeutische Zeitung.
https://doi.org/10.1002/14651858.CD006207.pub6
Jefferson, T., Dooley, L., Ferroni, E., Al-Ansary, L. A., Driel, M. L. van, Bawazeer, G. A., Jones, M. A., Hoffmann, T. C., Clark, J., Beller, E. M., Glasziou, P. P., & Conly, J. M. (2023). Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database of Systematic Reviews, 1.
https://doi.org/10.1002/14651858.CD004879.pub5
Jefferson, T., Rivetti, A., Pietrantonj, C. D., & Demicheli, V. (2018). Vaccines for preventing influenza in healthy children. Cochrane Database of Systematic Reviews, 2.
https://doi.org/10.1371/journal.pone.0220910
Jeong, S., Jang, E. J., Jo, J., & Jang, S. (2019). Effects of maternal influenza vaccination on adverse birth outcomes: A systematic review and Bayesian meta-analysis. PLoS ONE, 14(8), e0220910.
http://www.ncbi.nlm.nih.gov/books/NBK537197/
Kalarikkal, S. M., & Jaishankar, G. B. (2023). Influenza Vaccine. In StatPearls. StatPearls Publishing.
https://doi.org/10.1093/ofid/ofac664
Kim, P., Coleman, B., Kwong, J. C., Plevneshi, A., Hassan, K., Green, K., McNeil, S. A., Armstrong, I., Gold, W. L., Gubbay, J., Katz, K., Kuster, S. P., Lovinsky, R., Matukas, L., Ostrowska, K., Richardson, D., & McGeer, A. (2023). Burden of Severe Illness Associated With Laboratory-Confirmed Influenza in Adults Aged 50-64 Years, 2010-2011 to 2016-2017. Open Forum Infectious Diseases, 10(1), ofac664.
13.03.202521:08
https://doi.org/10.1503/cmaj.061435
Dodds, L., McNeil, S. A., Fell, D. B., Allen, V. M., Coombs, A., Scott, J., & MacDonald, N. (2007). Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women. CMAJ : Canadian Medical Association Journal, 176(4), 463–468.
https://doi.org/10.1080/14760584.2024.2331073
Domnich, A., Orsi, A., Signori, A., Chironna, M., Manini, I., Napoli, C., Rizzo, C., Panatto, D., & Icardi, G. (2024). Waning intra-season vaccine effectiveness against influenza A(H3N2) underlines the need for more durable protection. Expert Review of Vaccines, 23(1), 380–388.
https://doi.org/10.3390/ijerph15092034
Donzelli, A. (2018). Influenza Vaccinations for All Pregnant Women? Better Evidence Is Needed. International Journal of Environmental Research and Public Health, 15(9), 2034.
https://doi.org/10.1080/21645515.2015.1086047
Dos Santos, G., Neumeier, E., & Bekkat-Berkani, R. (2015). Influenza: Can we cope better with the unpredictable? Human Vaccines & Immunotherapeutics, 12(3), 699–708.
https://doi.org/10.1097/INF.0000000000002406
Eun, B. W., Lee, T. J., Lee, J., Kim, K. H., Kim, D. H., Jo, D. S., Shin, S. H., Kim, H., Kim, K.-H., & Kim, Y.-K. (2019). A Randomized, Double-blind, Active-controlled Phase III Trial of a Cell Culture-derived Quadrivalent Inactivated Influenza Vaccine in Healthy South Korean Children and Adolescents 6 Months to 18 Years of Age. The Pediatric Infectious Disease Journal, 38(9), e209–e215.
https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet
European Centre for Disease Prevention and Control. (2017, Juni 14). Factsheet about seasonal influenza. Ecdc.
https://www.ecdc.europa.eu/sites/default/files/documents/Systematic-review-update-enhanced-seasonal%20flu-vaccines.pdf
European Centre for Disease Prevention and Control. (2024, April). Systematic review of the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over. Ecdc.Europa.Eu.
https://www.ema.europa.eu/en/medicines/human/EPAR/supemtek
European Medicines Agency. (2020, November 25). Supemtek | European Medicines Agency (EMA). Ema.Europa.Eu.
https://www.ema.europa.eu/de/documents/product-information/fluenz-epar-product-information_de.pdf
European Medicines Agency. (2024a, Juli 22). Fluenz 2024/2025 Fachinformation. Ema.Europa.Eu.
https://www.ema.europa.eu/de/documents/product-information/flucelvax-tetra-epar-product-information_de.pdf
European Medicines Agency. (2024b, Juli 31). Flucelvax Tetra 2024/2025. Ema.Europa.Eu.
https://www.ema.europa.eu/de/documents/product-information/fluad-tetra-epar-product-information_de.pdf
European Medicines Agency. (2024c, August 1). Fluad Tetra 2024/2025 Fachinformation. Ema.Europa.Eu.
https://doi.org/10.2807/1560-7917.ES.2023.28.29.2300056
Fischer, N., Moreels, S., Dauby, N., Reynders, M., Petit, E., Gérard, M., Lacor, P., Daelemans, S., Lissoir, B., Holemans, X., Magerman, K., Jouck, D., Bourgeois, M., Delaere, B., Quoilin, S., Gucht, S. V., Thomas, I., Bossuyt, N., & Barbezange, C. (2023). Influenza versus other respiratory viruses – assessing severity among hospitalised children, Belgium, 2011 to 2020. Eurosurveillance, 28(29), 2300056.
https://doi.org/10.1016/j.gheart.2014.08.004
Fischer, W. A., Gong, M., Bhagwanjee, S., & Sevransky, J. (2014). Global burden of Influenza: Contributions from Resource Limited and Low-Income Settings. Global heart, 9(3), 325–336.
https://doi.org/10.1097/MOP.0000000000000712
Gavigan, P., & McCullers, J. A. (2019). Influenza: Annual seasonal severity. Current Opinion in Pediatrics, 31(1), 112–118.
https://doi.org/10.4049/jimmunol.1801010
Gounder, A. P., & Boon, A. C. M. (2019). Influenza Pathogenesis: The role of host factors on severity of disease. Journal of immunology (Baltimore, Md. : 1950), 202(2), 341–350.
Dodds, L., McNeil, S. A., Fell, D. B., Allen, V. M., Coombs, A., Scott, J., & MacDonald, N. (2007). Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women. CMAJ : Canadian Medical Association Journal, 176(4), 463–468.
https://doi.org/10.1080/14760584.2024.2331073
Domnich, A., Orsi, A., Signori, A., Chironna, M., Manini, I., Napoli, C., Rizzo, C., Panatto, D., & Icardi, G. (2024). Waning intra-season vaccine effectiveness against influenza A(H3N2) underlines the need for more durable protection. Expert Review of Vaccines, 23(1), 380–388.
https://doi.org/10.3390/ijerph15092034
Donzelli, A. (2018). Influenza Vaccinations for All Pregnant Women? Better Evidence Is Needed. International Journal of Environmental Research and Public Health, 15(9), 2034.
https://doi.org/10.1080/21645515.2015.1086047
Dos Santos, G., Neumeier, E., & Bekkat-Berkani, R. (2015). Influenza: Can we cope better with the unpredictable? Human Vaccines & Immunotherapeutics, 12(3), 699–708.
https://doi.org/10.1097/INF.0000000000002406
Eun, B. W., Lee, T. J., Lee, J., Kim, K. H., Kim, D. H., Jo, D. S., Shin, S. H., Kim, H., Kim, K.-H., & Kim, Y.-K. (2019). A Randomized, Double-blind, Active-controlled Phase III Trial of a Cell Culture-derived Quadrivalent Inactivated Influenza Vaccine in Healthy South Korean Children and Adolescents 6 Months to 18 Years of Age. The Pediatric Infectious Disease Journal, 38(9), e209–e215.
https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet
European Centre for Disease Prevention and Control. (2017, Juni 14). Factsheet about seasonal influenza. Ecdc.
https://www.ecdc.europa.eu/sites/default/files/documents/Systematic-review-update-enhanced-seasonal%20flu-vaccines.pdf
European Centre for Disease Prevention and Control. (2024, April). Systematic review of the efficacy, effectiveness and safety of newer and enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over. Ecdc.Europa.Eu.
https://www.ema.europa.eu/en/medicines/human/EPAR/supemtek
European Medicines Agency. (2020, November 25). Supemtek | European Medicines Agency (EMA). Ema.Europa.Eu.
https://www.ema.europa.eu/de/documents/product-information/fluenz-epar-product-information_de.pdf
European Medicines Agency. (2024a, Juli 22). Fluenz 2024/2025 Fachinformation. Ema.Europa.Eu.
https://www.ema.europa.eu/de/documents/product-information/flucelvax-tetra-epar-product-information_de.pdf
European Medicines Agency. (2024b, Juli 31). Flucelvax Tetra 2024/2025. Ema.Europa.Eu.
https://www.ema.europa.eu/de/documents/product-information/fluad-tetra-epar-product-information_de.pdf
European Medicines Agency. (2024c, August 1). Fluad Tetra 2024/2025 Fachinformation. Ema.Europa.Eu.
https://doi.org/10.2807/1560-7917.ES.2023.28.29.2300056
Fischer, N., Moreels, S., Dauby, N., Reynders, M., Petit, E., Gérard, M., Lacor, P., Daelemans, S., Lissoir, B., Holemans, X., Magerman, K., Jouck, D., Bourgeois, M., Delaere, B., Quoilin, S., Gucht, S. V., Thomas, I., Bossuyt, N., & Barbezange, C. (2023). Influenza versus other respiratory viruses – assessing severity among hospitalised children, Belgium, 2011 to 2020. Eurosurveillance, 28(29), 2300056.
https://doi.org/10.1016/j.gheart.2014.08.004
Fischer, W. A., Gong, M., Bhagwanjee, S., & Sevransky, J. (2014). Global burden of Influenza: Contributions from Resource Limited and Low-Income Settings. Global heart, 9(3), 325–336.
https://doi.org/10.1097/MOP.0000000000000712
Gavigan, P., & McCullers, J. A. (2019). Influenza: Annual seasonal severity. Current Opinion in Pediatrics, 31(1), 112–118.
https://doi.org/10.4049/jimmunol.1801010
Gounder, A. P., & Boon, A. C. M. (2019). Influenza Pathogenesis: The role of host factors on severity of disease. Journal of immunology (Baltimore, Md. : 1950), 202(2), 341–350.
13.03.202521:08
https://doi.org/10.2807/1560-7917.ES.2016.21.16.30201
Kissling, E., Nunes, B., Robertson, C., Valenciano, M., Reuss, A., Larrauri, A., Cohen, J. M., Oroszi, B., Rizzo, C., Machado, A., Pitigoi, D., Domegan, L., Paradowska-Stankiewicz, I., Buchholz, U., Gherasim, A., Daviaud, I., Horváth, J. K., Bella, A., Lupulescu, E., O Donnell, J., … I-MOVE case–control study team (2016). I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 21(16), 10.2807/1560-7917.ES.2016.21.16.30201.
https://doi.org/10.1007/s12098-016-2232-x
Kumar, V. (2017). Influenza in Children. Indian Journal of Pediatrics, 84(2), 139–143.
https://doi.org/10.1126/sciadv.adq7006
Kumar, S., Zoodsma, M., Nguyen, N., Pedroso, R., Trittel, S., Riese, P., Botey-Bataller, J., Zhou, L., Alaswad, A., Arshad, H., Netea, M. G., Xu, C.-J., Pessler, F., Guzmán, C. A., Graca, L., & Li, Y. (2024). Systemic dysregulation and molecular insights into poor influenza vaccine response in the aging population. Science Advances, 10(39), eadq7006.
https://doi.org/10.1086/520101
Leekha, S., Zitterkopf, N. L., Espy, M. J., Smith, T. F., Thompson, R. L., & Sampathkumar, P. (2007). Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infection Control and Hospital Epidemiology, 28(9), 1071–1076.
https://doi.org/10.1038/s41579-021-00535-6
Leung, N. H. L. (2021). Transmissibility and transmission of respiratory viruses. Nature Reviews. Microbiology, 19(8), 528–545.
https://doi.org/10.1016/j.coviro.2020.08.004
Liu, R., Sheng, Z., Huang, C., Wang, D., & Li, F. (2020). Influenza D Virus. Current opinion in virology, 44, 154–161.
https://doi.org/10.1016/j.vaccine.2024.01.040
Liu, R., Fan, Y., Patel, A., Liu, H., Du, X., Liu, B., & Di Tanna, G. L. (2024). The association between influenza vaccination, cardiovascular mortality and hospitalization: living systematic review and prospective meta-analysis. Vaccine, 42(5), 1034–1041.
https://doi.org/10.1016/j.lanepe.2021.100029
Lusignan, S. de, Tsang, R. S. M., Amirthalingam, G., Akinyemi, O., Sherlock, J., Tripathy, M., Deeks, A., Ferreira, F., Howsam, G., Hobbs, F. D. R., & Joy, M. (2021). Adverse events of interest following influenza vaccination, a comparison of cell culture-based with egg-based alternatives: English sentinel network annual report paper 2019/20. The Lancet Regional Health – Europe, 2.
https://doi.org/10.1136/bmj.p1445
Mahase, E. (2023). Flu deaths in UK hit five year high last winter. BMJ, 381, p1445.
https://doi.org/10.1093/infdis/jiy370
Maier, H. E., Lopez, R., Sanchez, N., Ng, S., Gresh, L., Ojeda, S., Burger-Calderon, R., Kuan, G., Harris, E., Balmaseda, A., & Gordon, A. (2018). Obesity Increases the Duration of Influenza A Virus Shedding in Adults. The Journal of Infectious Diseases, 218(9), 1378–1382.
https://doi.org/10.2807/1560-7917.ES.2016.21.42.30378
Mertz, D., Fadel, S. A., Lam, P.-P., Tran, D., Srigley, J. A., Asner, S. A., Science, M., Kuster, S. P., Nemeth, J., Johnstone, J., Ortiz, J. R., & Loeb, M. (2016). Herd effect from influenza vaccination in non-healthcare settings: A systematic review of randomised controlled trials and observational studies. Eurosurveillance, 21(42), 30378.
https://doi.org/10.1056/NEJMp2314801
Moghadami, M. (2017). A Narrative Review of Influenza: A Seasonal and Pandemic Disease. Iranian Journal of Medical Sciences, 42(1), 2–13.
Monto, A. S., Zambon, M., & Weir, J. P. (2024). The End of B/Yamagata Influenza Transmission—Transitioning from Quadrivalent Vaccines. The New England Journal of Medicine.
https://doi.org/10.1007/978-1-4939-8678-1_22
Neumann, G., Fan, S., & Kawaoka, Y. (2018). Selection of Antigenically Advanced Variants of Influenza Viruses. Methods in Molecular Biology (Clifton, N.J.), 1836, 461–486.
Kissling, E., Nunes, B., Robertson, C., Valenciano, M., Reuss, A., Larrauri, A., Cohen, J. M., Oroszi, B., Rizzo, C., Machado, A., Pitigoi, D., Domegan, L., Paradowska-Stankiewicz, I., Buchholz, U., Gherasim, A., Daviaud, I., Horváth, J. K., Bella, A., Lupulescu, E., O Donnell, J., … I-MOVE case–control study team (2016). I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination?. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 21(16), 10.2807/1560-7917.ES.2016.21.16.30201.
https://doi.org/10.1007/s12098-016-2232-x
Kumar, V. (2017). Influenza in Children. Indian Journal of Pediatrics, 84(2), 139–143.
https://doi.org/10.1126/sciadv.adq7006
Kumar, S., Zoodsma, M., Nguyen, N., Pedroso, R., Trittel, S., Riese, P., Botey-Bataller, J., Zhou, L., Alaswad, A., Arshad, H., Netea, M. G., Xu, C.-J., Pessler, F., Guzmán, C. A., Graca, L., & Li, Y. (2024). Systemic dysregulation and molecular insights into poor influenza vaccine response in the aging population. Science Advances, 10(39), eadq7006.
https://doi.org/10.1086/520101
Leekha, S., Zitterkopf, N. L., Espy, M. J., Smith, T. F., Thompson, R. L., & Sampathkumar, P. (2007). Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infection Control and Hospital Epidemiology, 28(9), 1071–1076.
https://doi.org/10.1038/s41579-021-00535-6
Leung, N. H. L. (2021). Transmissibility and transmission of respiratory viruses. Nature Reviews. Microbiology, 19(8), 528–545.
https://doi.org/10.1016/j.coviro.2020.08.004
Liu, R., Sheng, Z., Huang, C., Wang, D., & Li, F. (2020). Influenza D Virus. Current opinion in virology, 44, 154–161.
https://doi.org/10.1016/j.vaccine.2024.01.040
Liu, R., Fan, Y., Patel, A., Liu, H., Du, X., Liu, B., & Di Tanna, G. L. (2024). The association between influenza vaccination, cardiovascular mortality and hospitalization: living systematic review and prospective meta-analysis. Vaccine, 42(5), 1034–1041.
https://doi.org/10.1016/j.lanepe.2021.100029
Lusignan, S. de, Tsang, R. S. M., Amirthalingam, G., Akinyemi, O., Sherlock, J., Tripathy, M., Deeks, A., Ferreira, F., Howsam, G., Hobbs, F. D. R., & Joy, M. (2021). Adverse events of interest following influenza vaccination, a comparison of cell culture-based with egg-based alternatives: English sentinel network annual report paper 2019/20. The Lancet Regional Health – Europe, 2.
https://doi.org/10.1136/bmj.p1445
Mahase, E. (2023). Flu deaths in UK hit five year high last winter. BMJ, 381, p1445.
https://doi.org/10.1093/infdis/jiy370
Maier, H. E., Lopez, R., Sanchez, N., Ng, S., Gresh, L., Ojeda, S., Burger-Calderon, R., Kuan, G., Harris, E., Balmaseda, A., & Gordon, A. (2018). Obesity Increases the Duration of Influenza A Virus Shedding in Adults. The Journal of Infectious Diseases, 218(9), 1378–1382.
https://doi.org/10.2807/1560-7917.ES.2016.21.42.30378
Mertz, D., Fadel, S. A., Lam, P.-P., Tran, D., Srigley, J. A., Asner, S. A., Science, M., Kuster, S. P., Nemeth, J., Johnstone, J., Ortiz, J. R., & Loeb, M. (2016). Herd effect from influenza vaccination in non-healthcare settings: A systematic review of randomised controlled trials and observational studies. Eurosurveillance, 21(42), 30378.
https://doi.org/10.1056/NEJMp2314801
Moghadami, M. (2017). A Narrative Review of Influenza: A Seasonal and Pandemic Disease. Iranian Journal of Medical Sciences, 42(1), 2–13.
Monto, A. S., Zambon, M., & Weir, J. P. (2024). The End of B/Yamagata Influenza Transmission—Transitioning from Quadrivalent Vaccines. The New England Journal of Medicine.
https://doi.org/10.1007/978-1-4939-8678-1_22
Neumann, G., Fan, S., & Kawaoka, Y. (2018). Selection of Antigenically Advanced Variants of Influenza Viruses. Methods in Molecular Biology (Clifton, N.J.), 1836, 461–486.
13.03.202521:08
https://doi.org/10.4140/TCP.n.2020.398
Barranco, D., & Chahine, E. B. (2020). Adjuvanted inactivated influenza Vaccine Quadrivalent for Older People. The Senior Care Pharmacist, 35(9), 398–402.
https://doi.org/10.1186/s12879-022-07727-2
Belizaire, M. R. D., N’gattia, A. K., Wassonguema, B., Simaleko, M. M., Nakoune, E., Rafaï, C., Lô, B., & Bolumar, F. (2022). Circulation and seasonality of influenza viruses in different transmission zones in Africa. BMC Infectious Diseases, 22(1), 820.
https://doi.org/10.1186/s12962-023-00432-0
Beresniak, A., Napoli, C., Oxford, J., Daruich, A., Niddam, L., Duru, G., Tozzi, A. E., Atti, M. C. D., Dupont, D., Rizzo, C., & Bremond-Gignac, D. (2023). The FLURESP European commission project: Cost-effectiveness assessment of ten public health measures against influenza in Italy: is there an interest in COVID-19 pandemic? Cost Effectiveness and Resource Allocation: C/E, 21(1), 30.
http://www.ncbi.nlm.nih.gov/books/NBK459363
Boktor, S. W., & Hafner, J. W. (2023). Influenza. In StatPearls. StatPearls Publishing.
https://doi.org/10.1101/2023.04.16.23288205
Brown, M., Gerrard, J., McKinlay, L., Marquess, J., Sparrow, T., & Andrews, R. (2023). Ongoing symptoms and functional impairment 12 weeks after testing positive to SARS-CoV-2 or influenza in Australia: An observational cohort study (S. 2023.04.16.23288205). medRxiv.
https://portal.dimdi.de/amguifree/am/searchresult.xhtml?accessid=amis_off_am_ppv&directdisplay=true&gripsQuery=STATUS=CURRENT+AND+ENR=2613962
Bundesinstitut für Arzneimittel und Medizinprodukte. (2023, Juli 1). Afluria Tetra Fachinformation. DIMDI.
https://portal.dimdi.de/amguifree/am/searchresult.xhtml?accessid=amis_off_am_ppv&directdisplay=true&gripsQuery=STATUS=CURRENT+AND+ENR=2612711
Bundesinstitut für Arzneimittel und Medizinprodukte. (2024a, April 1). Influsplit Tetra 2024/2025 Fachinformation. DIMDI.
https://portal.dimdi.de/amguifree/am/searchresult.xhtml?accessid=amis_off_am_ppv&directdisplay=true&gripsQuery=STATUS=CURRENT+AND+ENR=2613624
Bundesinstitut für Arzneimittel und Medizinprodukte. (2024b, Mai 1). Vaxigrip Tetra 2024/2025 Fachinformation. DIMDI.
https://portal.dimdi.de/amguifree/am/searchresult.xhtml?accessid=amis_off_am_ppv&directdisplay=true&gripsQuery=STATUS=CURRENT+AND+ENR=2613953
Bundesinstitut für Arzneimittel und Medizinprodukte. (2024c, Juni 1). Elflueda Tetra 2024/2025 Fachinformation. DIMDI.
https://portal.dimdi.de/amguifree/am/searchresult.xhtml?accessid=amis_off_am_ppv&directdisplay=true&gripsQuery=STATUS=CURRENT+AND+ENR=2613725
Bundesinstitut für Arzneimittel und Medizinprodukte. (2024d, Juni 1). Influvac Tetra 2024/2025 Fachinformation. DIMDI.
https://portal.dimdi.de/amguifree/am/searchresult.xhtml?accessid=amis_off_am_ppv&directdisplay=true&gripsQuery=STATUS=CURRENT+AND+ENR=2613624
Bundesinstitut für Arzneimittel und Medizinprodukte. (2024e, Juni 1). Xanaflu Tetra 2024/2025 Fachinformation. DIMDI.
https://portal.dimdi.de/amguifree/am/searchresult.xhtml?accessid=amis_off_am_ppv&directdisplay=true&gripsQuery=STATUS=CURRENT+AND+ENR=7016858
Bundesinstitut für Arzneimittel und Medizinprodukte. (2024f, Juli 1). Influvac 2024/2025 Fachinformation. DIMDI.
https://portal.dimdi.de/amguifree/am/searchresult.xhtml?accessid=amis_off_am_ppv&directdisplay=true&gripsQuery=STATUS=CURRENT+AND+ENR=7016859
Bundesinstitut für Arzneimittel und Medizinprodukte. (2024g, Juli 1). Xanaflu 2024/2025 Fachinformation. DIMDI.
https://doi.org/10.1016/B978-0-12-375156-0.00039-4
Burrell, C. J., Howard, C. R., & Murphy, F. A. (2017). Chapter 39—Viral Syndromes. In C. J. Burrell, C. R. Howard, & F. A. Murphy (Hrsg.), Fenner and White’s Medical Virology (Fifth Edition) (S. 537–556). Academic Press.
Barranco, D., & Chahine, E. B. (2020). Adjuvanted inactivated influenza Vaccine Quadrivalent for Older People. The Senior Care Pharmacist, 35(9), 398–402.
https://doi.org/10.1186/s12879-022-07727-2
Belizaire, M. R. D., N’gattia, A. K., Wassonguema, B., Simaleko, M. M., Nakoune, E., Rafaï, C., Lô, B., & Bolumar, F. (2022). Circulation and seasonality of influenza viruses in different transmission zones in Africa. BMC Infectious Diseases, 22(1), 820.
https://doi.org/10.1186/s12962-023-00432-0
Beresniak, A., Napoli, C., Oxford, J., Daruich, A., Niddam, L., Duru, G., Tozzi, A. E., Atti, M. C. D., Dupont, D., Rizzo, C., & Bremond-Gignac, D. (2023). The FLURESP European commission project: Cost-effectiveness assessment of ten public health measures against influenza in Italy: is there an interest in COVID-19 pandemic? Cost Effectiveness and Resource Allocation: C/E, 21(1), 30.
http://www.ncbi.nlm.nih.gov/books/NBK459363
Boktor, S. W., & Hafner, J. W. (2023). Influenza. In StatPearls. StatPearls Publishing.
https://doi.org/10.1101/2023.04.16.23288205
Brown, M., Gerrard, J., McKinlay, L., Marquess, J., Sparrow, T., & Andrews, R. (2023). Ongoing symptoms and functional impairment 12 weeks after testing positive to SARS-CoV-2 or influenza in Australia: An observational cohort study (S. 2023.04.16.23288205). medRxiv.
https://portal.dimdi.de/amguifree/am/searchresult.xhtml?accessid=amis_off_am_ppv&directdisplay=true&gripsQuery=STATUS=CURRENT+AND+ENR=2613962
Bundesinstitut für Arzneimittel und Medizinprodukte. (2023, Juli 1). Afluria Tetra Fachinformation. DIMDI.
https://portal.dimdi.de/amguifree/am/searchresult.xhtml?accessid=amis_off_am_ppv&directdisplay=true&gripsQuery=STATUS=CURRENT+AND+ENR=2612711
Bundesinstitut für Arzneimittel und Medizinprodukte. (2024a, April 1). Influsplit Tetra 2024/2025 Fachinformation. DIMDI.
https://portal.dimdi.de/amguifree/am/searchresult.xhtml?accessid=amis_off_am_ppv&directdisplay=true&gripsQuery=STATUS=CURRENT+AND+ENR=2613624
Bundesinstitut für Arzneimittel und Medizinprodukte. (2024b, Mai 1). Vaxigrip Tetra 2024/2025 Fachinformation. DIMDI.
https://portal.dimdi.de/amguifree/am/searchresult.xhtml?accessid=amis_off_am_ppv&directdisplay=true&gripsQuery=STATUS=CURRENT+AND+ENR=2613953
Bundesinstitut für Arzneimittel und Medizinprodukte. (2024c, Juni 1). Elflueda Tetra 2024/2025 Fachinformation. DIMDI.
https://portal.dimdi.de/amguifree/am/searchresult.xhtml?accessid=amis_off_am_ppv&directdisplay=true&gripsQuery=STATUS=CURRENT+AND+ENR=2613725
Bundesinstitut für Arzneimittel und Medizinprodukte. (2024d, Juni 1). Influvac Tetra 2024/2025 Fachinformation. DIMDI.
https://portal.dimdi.de/amguifree/am/searchresult.xhtml?accessid=amis_off_am_ppv&directdisplay=true&gripsQuery=STATUS=CURRENT+AND+ENR=2613624
Bundesinstitut für Arzneimittel und Medizinprodukte. (2024e, Juni 1). Xanaflu Tetra 2024/2025 Fachinformation. DIMDI.
https://portal.dimdi.de/amguifree/am/searchresult.xhtml?accessid=amis_off_am_ppv&directdisplay=true&gripsQuery=STATUS=CURRENT+AND+ENR=7016858
Bundesinstitut für Arzneimittel und Medizinprodukte. (2024f, Juli 1). Influvac 2024/2025 Fachinformation. DIMDI.
https://portal.dimdi.de/amguifree/am/searchresult.xhtml?accessid=amis_off_am_ppv&directdisplay=true&gripsQuery=STATUS=CURRENT+AND+ENR=7016859
Bundesinstitut für Arzneimittel und Medizinprodukte. (2024g, Juli 1). Xanaflu 2024/2025 Fachinformation. DIMDI.
https://doi.org/10.1016/B978-0-12-375156-0.00039-4
Burrell, C. J., Howard, C. R., & Murphy, F. A. (2017). Chapter 39—Viral Syndromes. In C. J. Burrell, C. R. Howard, & F. A. Murphy (Hrsg.), Fenner and White’s Medical Virology (Fifth Edition) (S. 537–556). Academic Press.
14.02.202512:50
Bill Gates:
„Ich mache mir Sorgen, besonders wegen dieser USAID-Sache. Meine Stiftung arbeitet mit USAID in Sachen Ernährung und Impfstoffe zusammen(…) Hoffentlich geht ein Teil dieser Arbeit weiter (…) Wenn nicht, könnte es Millionen von Toten geben.“
t.me/Rosenbusch
„Ich mache mir Sorgen, besonders wegen dieser USAID-Sache. Meine Stiftung arbeitet mit USAID in Sachen Ernährung und Impfstoffe zusammen(…) Hoffentlich geht ein Teil dieser Arbeit weiter (…) Wenn nicht, könnte es Millionen von Toten geben.“
t.me/Rosenbusch
显示 1 - 13 共 13
登录以解锁更多功能。